CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,106,536 | +43.5% | 37,207 | -13.1% | 0.00% | 0.0% |
| Q2 2023 | $771,183 | +51.4% | 42,796 | +34.9% | 0.00% | 0.0% |
| Q1 2023 | $509,424 | -6.2% | 31,720 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $543,181 | -11.1% | 29,682 | -4.5% | 0.00% | 0.0% |
| Q3 2022 | $611,000 | +19.6% | 31,066 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $511,000 | -6.6% | 27,436 | +10.1% | 0.00% | – |
| Q1 2022 | $547,000 | -5.2% | 24,930 | +22.7% | 0.00% | – |
| Q4 2021 | $577,000 | +89.8% | 20,317 | +41.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.0% | 14,382 | +0.6% | 0.00% | – |
| Q2 2021 | $269,000 | +68.1% | 14,290 | +36.2% | 0.00% | – |
| Q1 2021 | $160,000 | -38.7% | 10,492 | -43.2% | 0.00% | – |
| Q4 2020 | $261,000 | +23.7% | 18,470 | +53.2% | 0.00% | – |
| Q2 2020 | $211,000 | – | 12,057 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |